Filing Overview
Issuer discrepancy: The supplied filing is Neuralstem, Inc. (NASDAQ: CUR), not Palisade Bio, Inc. It is a Form 10-K for the fiscal year ended December 31, 2015, with unaudited fourth-quarter data included.
Business Context and Reporting Period
Neuralstem was a clinical-stage biotechnology company developing central nervous system therapies based on human neural stem cells and small-molecule compounds. Its principal programs were NSI-189 for major depressive disorder and NSI-566 for ALS, spinal cord injury, and ischemic stroke. No product had received regulatory approval or generated commercial sales.
- NSI-189: FDA Phase II authorization was received after year-end, with first enrollment expected in the second quarter of 2016.
- NSI-566 ALS: Phase II dosing was completed; the trial met primary safety endpoints and established a reported maximum tolerated dose of 16 million cells.
- NSI-566 spinal cord injury: Four-subject Phase I study showed feasibility and safety, with no serious adverse events; only one subject showed reported functional improvement.
- NSI-566 ischemic stroke: The China trial had completed dosing in two of three planned cohorts.
Financial Results and Key Metrics
| Metric | FY 2015 | FY 2014 | Change |
|---|---|---|---|
| Revenue | $10,417 | $18,833 | Down 45% |
| Operating expenses | $19.17 million | $17.45 million | Up 10% |
| Operating loss | $19.16 million | $17.44 million | Loss increased 10% |
| Net loss | $20.90 million | $22.63 million | Loss improved 8% |
| Basic and diluted loss per share | $0.23 | $0.26 | Improved |
| Net cash used in operations | $18.93 million | $11.71 million | Use increased 62% |
| Cash and cash equivalents | $4.72 million | $12.52 million | Down 62% |
| Short-term investments | $7.52 million | $15.01 million | Down 50% |
| Cash and short-term investments | $12.23 million | $27.53 million | Down 56% |
| Long-term debt, net | $8.03 million | $8.79 million | Down 9% |
| Working capital | $7.01 million | $24.15 million | Down 71% |
Revenue consisted of licensing and related fees; the company generated no revenue from product sales. The filing does not provide a meaningful revenue-based margin because revenue was immaterial relative to operating expenses. Research and development expense increased to $12.64 million from $8.36 million, while general and administrative expense declined to $6.53 million from $9.09 million.
Investing activities provided $7.25 million, primarily from maturities of short-term investments. Financing activities provided $3.89 million, including approximately $2.93 million from stock sales and $3.07 million from warrant exercises, partially offset by debt repayments.
Material Changes Versus the Prior Period
- Research and development spending increased 51%, driven by higher payroll, headcount, project, laboratory, preclinical, and clinical-trial activity.
- General and administrative expense declined 28%, primarily because 2014 included significant non-cash stock-based compensation and higher legal, consulting, and advisory costs.
- Other expense declined to $1.75 million from $5.19 million because the $3.11 million warrant-modification expense, $446,000 debt-extinguishment loss, and $334,000 derivative fair-value loss recorded in 2014 did not recur.
- Liquidity deteriorated materially as operating cash use rose and cash plus short-term investments fell by approximately $15.29 million.
- Shares outstanding increased to 92.01 million from 87.79 million, reflecting equity issuance and exercises of options and warrants.
Fourth-Quarter 2015 Data
| Metric | Q4 2015 | Q4 2014 |
|---|---|---|
| Revenue | $2,500 | $4,666 |
| Operating loss | $4.35 million | $4.64 million |
| Net loss | $4.77 million | $5.50 million |
| Basic and diluted loss per share | $0.05 | $0.06 |
Guidance, Outlook, Risks, and Unusual Items
- Management expected continuing operating losses and did not expect profitability in the next several years.
- Cash and cash equivalents plus short-term investments were expected to fund operations for only five to six months after December 31, 2015, approximately through June 2016.
- The auditors included substantial doubt regarding the company’s ability to continue as a going concern. Additional equity or debt financing was essential; failure to obtain financing could require reducing or stopping trials, curtailing operations, or filing for bankruptcy.
- The company had approximately $8.34 million of aggregate principal debt. Contractual debt payments were approximately $4.57 million in 2016 and $3.77 million in 2017, including a balloon payment of approximately $2.8 million in April 2017. Substantially all assets, including intellectual property, secured the debt.
- Management was pursuing external funding for clinical programs. In January 2016, it announced a strategic refocusing toward NSI-189 and plans to seek outside funding for substantially all NSI-566 costs.
- Key risks included clinical-trial failure or delay, uncertain FDA approval, dependence on third-party manufacturers and clinical organizations, intellectual-property challenges, competition, product liability, dilution from future financing, and limited commercial experience.
- Subsequent events included the appointment of Richard Daly as CEO and President in February 2016, the departure of Richard Garr as CEO, and a severance arrangement involving continued salary, three $177,000 payments, healthcare benefits, and accelerated equity vesting.
Investor Verification Priorities
- Verify the issuer identity: the provided document is Neuralstem, Inc., while the request identifies Palisade Bio, Inc.
- Confirm whether subsequent financing occurred and whether it extended liquidity beyond the stated June 2016 runway.
- Review debt covenants, required monthly payments, the April 2017 balloon payment, and collateral provisions.
- Track FDA status, enrollment, endpoints, and funding for the NSI-189 Phase II trial and the NSI-566 programs.
- Assess dilution from outstanding options, warrants, restricted awards, and anticipated capital raises.
- Review the going-concern disclosure, accumulated deficit of approximately $171.96 million, and the absence of product revenue.
- Confirm the resolution and continuing implications of the disclosed intellectual-property litigation and executive severance obligations.